Prevention of Liver Damage During Liver Surgery (LTR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Ludwig-Maximilians - University of Munich.
Recruitment status was  Active, not recruiting
Information provided by:
Ludwig-Maximilians - University of Munich Identifier:
First received: February 17, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
Liver damage as a consequnce of ischemia (I) and reperfusion (R) is known to harm the liver and could hence be a critical factor of the postoperative outcome of patients undergoing liver surgery. In order to protect the liver from ischemic damage following interventions such as the Pringle Maneuver, preconditioning has been successfully applied in various animal models as well as in humans. Since ischemia inevitably leads to cell hypoxia and subsequnet release of endogenuous metabolites, the investigators hypothesize that instead of brief periods of ischemia, the exogenuous infusion of purine analogues may also protect against subsequent prolonged periods of ischemia. Moreover, after reperfusion, the antiinflamamtory action of purine ananlogue infusion can further attenuated liver damage.

Condition Intervention Phase
Liver Tumors
Drug: placebo
Drug: adenosine
Procedure: Liver resection
Phase 1
Phase 2

Study Type: Interventional
Official Title: Study on the Potential Role of Intraoperative Hepatoprotection During Liver Resections

Resource links provided by NLM:

Further study details as provided by Ludwig-Maximilians - University of Munich:

Arms Assigned Interventions
Placebo Comparator: 1
liver resection with Pringle + placebo
Drug: placebo
NaCl 0,9 %
Procedure: Liver resection
Liver resection with Pringle maneuver
Active Comparator: 2
liver resection with Pringle + adenosine preconditiong
Drug: adenosine
intravenous infusion of adenosine 0, 2 %
Procedure: Liver resection
Liver resection with Pringle maneuver
Active Comparator: 3
liver resection with Pringle + adenosine pre- and postconditioning
Drug: adenosine
intravenous infusion of adenosine 0,2 %
Procedure: Liver resection
Liver resection with Pringle maneuver



Inclusion Criteria:

  • elective resection of liver tumors
  • age 18 to 80 years
  • informed consent

Exclusion Criteria:

  • chronic obstructive pulmonary disease
  • heart insufficiency NYHA III-IV
  • atrio-ventricular conductance blockage II. (Mobitz) or III. degree
  • atrial fibrillation
  • coronary heart disease (CCS III. or IV. degree)
  • arterial hypertension
  • acute renal failure
  • increased intracranial pressure
  • gout
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Prof. Dr. Manfred Thiel, Department of Anaesthesiology of the Ludwig-Maximilians-University Identifier: NCT00845689     History of Changes
Other Study ID Numbers: LMU-202-LTR 
Study First Received: February 17, 2009
Last Updated: February 17, 2009
Health Authority: Germany: Institutional Review Board
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Ludwig-Maximilians - University of Munich:
liver surgery

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Cardiovascular Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Vasodilator Agents processed this record on May 04, 2016